Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.1K
Tissue Transplantation01:24

Tissue Transplantation

1.4K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial.

JMIR mHealth and uHealth·2026
Same author

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

American journal of hematology·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.

Cancer medicine·2025
Same author

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results.

Clinical pharmacology and therapeutics·2025
Same author

SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance.

Clinical lymphoma, myeloma & leukemia·2025

Related Experiment Video

Updated: May 6, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Allogeneic transplantation in multiple myeloma.

Gösta Gahrton1, Amrita Krishnan

  • 1Department of Medicine, Karolinska Institutet, Huddinge, SE 14186 Stockholm, Sweden.

Expert Review of Hematology
|November 15, 2013
PubMed
Summary

Reduced-intensity allogeneic transplantation (RICallo) offers a safer alternative for multiple myeloma patients. Upfront tandem autologous/RICallo strategies show promise in improving survival outcomes, especially for specific patient subgroups.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation immunology

Background:

  • Allogeneic transplantation can cure multiple myeloma but faces challenges due to high mortality.
  • Myeloablative allogeneic transplantation is less favored; reduced-intensity conditioning allogeneic transplantation (RICallo) presents a lower-risk option.
  • The efficacy of upfront tandem autologous/RICallo (auto/RICallo) versus autologous approaches requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of upfront tandem autologous/RICallo (auto/RICallo) compared to single autologous or tandem autologous/autologous transplantation in multiple myeloma.
  • To assess the potential of auto/RICallo in overcoming poor-risk cytogenetics and treating relapsed multiple myeloma.
  • To explore novel combinations of allotransplantation with emerging therapies.

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Related Experiment Videos

Last Updated: May 6, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Main Methods:

  • Analysis of two studies with long-term follow-up comparing upfront tandem auto/RICallo to auto or auto/auto.
  • Review of four similarly designed studies with shorter follow-up periods.
  • Examination of preliminary data on auto/RICallo for relapsed disease and poor-risk cytogenetics.

Main Results:

  • Two long-term studies demonstrated superior progression-free and overall survival with upfront tandem auto/RICallo compared to single auto or tandem auto/auto.
  • Four shorter-term studies did not find a significant advantage for the auto/RICallo approach.
  • No study indicated that auto/RICallo is inferior to autologous-only strategies; promising results observed in relapsed patients.

Conclusions:

  • Upfront tandem autologous/RICallo may offer survival benefits in specific multiple myeloma patient subgroups, particularly those with poor-risk cytogenetics.
  • Further prospective studies combining allotransplantation with novel agents like proteasome inhibitors and immunomodulatory drugs are warranted.
  • Investigating new cell therapies, such as natural killer cells, in conjunction with allotransplantation holds future therapeutic potential.